6 recruiting, 4 terminated, 2 completed, 2 withdrawn. 6 Phase 2, 5 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 3, Completed 2, Recruiting 1 |
| Phase 1 | 5 | Terminated 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 3 | Recruiting | Newave Pharmaceutical Inc | 306 | 2026-04-23 | 2026-11-10 |
| Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients - CLL, CAR-T Cell Therapy | Not applicable | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-13 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 735 | 2023-08-08 | 2026-11-06 |
| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia CAP-100 - Lymphocytic Leukemia, Chronic, SLL | Phase 1 | Recruiting | Catapult Therapeutics | 18 | 2021-09-10 | 2025-07-17 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Treatment Free Observation - CLL, SLL | Withdrawn | Memorial Sloan Kettering Cancer Center | 2020-12-22 | 2025-05-16 | ||
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) A6 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Ångstrom Pharmaceuticals | 5 | 2014-02-01 | 2016-07-13 |
| Registry of the German CLL Study Group CLL, SLL | Recruiting | German CLL Study Group | 8000 | 2013-08-01 | 2025-12-08 | |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma rituximab, bortezomib, cladribine - Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | University of Arizona | 24 | 2009-07-07 | 2019-12-30 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Follicular (3) · Leukemia (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Recurrence (2) · Chromosome 17 deletion (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, B-Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Prolymphocytic (1) · Leukemia, Prolymphocytic, B-Cell (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Neoplasms by Histologic Type (12) · Hematologic Diseases (11) · Leukemia, Lymphoid (11) · Neoplasms (11) · Chronic Disease (10) · Disease Attributes (10) · Leukemia, B-Cell (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Leukemia (9)
Rituximab (2) · ARQ531 (1) · Alemtuzumab (1) · Bortezomib (1) · Cladribine (1) · LFB-R603 (1) · Methylprednisolone (1) · dubermatinib (1) · ofatumumab (1) · pirtobrutinib (1) · ublituximab (1) · veltuzumab (1) · venetoclax (1)
Catapult Therapeutics (1) · Dana-Farber Cancer Institute (1) · German CLL Study Group (1) · Gilead Sciences (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Newave Pharmaceutical Inc (1) · Sumitomo Pharma America, Inc. (1) · TG Therapeutics, Inc. (1) · The Affiliated Hospital of Xuzhou Medical University (1) · University of Arizona (1) · Virginia Commonwealth University (1) · Zulfa Omer (1) · Ångstrom Pharmaceuticals (1)
United States (11) · Germany (2) · Spain (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Colombia (1) · France (1) · Greece (1) · Israel (1) · Italy (1)
Anthony Mato, MD (1) · Daniel O. Persky, MD (1) · Jennifer R Brown, MD PhD (1) · Michael Choi, MD (1) · Michael Hallek, MD (1) · Phillip Komarnitsky (1) · Victor Y Yazbek, MD, MS (1) · William Wegener, MD, PhD (1)
PMID 21173095, PMID 26389849, PMID 29056470, PMID 30322319, PMID 35538512, PMID 37358640
P30CA023074 (1)